Melanoma Drugs - $13.98 Billion Industry Opportunity Assessment, 2024-2028: Regional Insights and Competitor Market Shares
24 janv. 2024 13h39 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Melanoma Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global melanoma drugs market has grown...
Nephrology Drugs Industry Report 2024-2033: Innovative Therapies, Precision Medicine, Telehealth, and Global Initiatives Driving the Market to Reach $21.53 Billion by 2028
24 janv. 2024 13h36 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Nephrology Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global nephrology drugs market has grown...
Acute Lymphoblastic Leukemia Treatment Market Poised for Growth, Forecasts 2024-2030: Spotlight on Emerging Therapies and Comprehensive Vendor Analysis
24 janv. 2024 08h49 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Acute Lymphoblastic Leukemia Treatment Market (ALL) by Types of Cell (B-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-),...
Global Pharmaceutical R&D Directory 2024: Development Pipeline of Major Companies, Analyzed by Therapeutic Categories and Stages
22 janv. 2024 06h13 HE
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical R&D Directory 2024" has been added to ResearchAndMarkets.com's offering.The Global Pharmaceutical R&D Directory provides...
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
18 janv. 2024 07h45 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Global Pharmaceuticals Market Analysis and Forecast to 2027, with Company Profiles of Key Market Players Bayer, Novartis ,Pfizer and Johnson & Johnson
04 janv. 2024 09h43 HE
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.The...
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
19 déc. 2023 09h00 HE
|
Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
Rafarma Pharmaceutical news update
30 nov. 2023 09h30 HE
|
Rafarma Pharmaceuticals Inc.
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet...
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
30 nov. 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
29 nov. 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...